DHA-enriched high-oleic acid canola oil improves lipid profile and lowers predicted cardiovascular disease risk in the canola oil multicenter randomized controlled trial.

BACKGROUND It is well recognized that amounts of trans and saturated fats should be minimized in Western diets; however, considerable debate remains regarding optimal amounts of dietary n-9, n-6, and n-3 fatty acids. OBJECTIVE The objective was to examine the effects of varying n-9, n-6, and longer-chain n-3 fatty acid composition on markers of coronary heart disease (CHD) risk. DESIGN A randomized, double-blind, 5-period, crossover design was used. Each 4-wk treatment period was separated by 4-wk washout intervals. Volunteers with abdominal obesity consumed each of 5 identical weight-maintaining, fixed-composition diets with one of the following treatment oils (60 g/3000 kcal) in beverages: 1) conventional canola oil (Canola; n-9 rich), 2) high-oleic acid canola oil with docosahexaenoic acid (CanolaDHA; n-9 and n-3 rich), 3) a blend of corn and safflower oil (25:75) (CornSaff; n-6 rich), 4) a blend of flax and safflower oils (60:40) (FlaxSaff; n-6 and short-chain n-3 rich), or 5) high-oleic acid canola oil (CanolaOleic; highest in n-9). RESULTS One hundred thirty individuals completed the trial. At endpoint, total cholesterol (TC) was lowest after the FlaxSaff phase (P < 0.05 compared with Canola and CanolaDHA) and highest after the CanolaDHA phase (P < 0.05 compared with CornSaff, FlaxSaff, and CanolaOleic). Low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol were highest, and triglycerides were lowest, after CanolaDHA (P < 0.05 compared with the other diets). All diets decreased TC and LDL cholesterol from baseline to treatment endpoint (P < 0.05). CanolaDHA was the only diet that increased HDL cholesterol from baseline (3.5 ± 1.8%; P < 0.05) and produced the greatest reduction in triglycerides (-20.7 ± 3.8%; P < 0.001) and in systolic blood pressure (-3.3 ± 0.8%; P < 0.001) compared with the other diets (P < 0.05). Percentage reductions in Framingham 10-y CHD risk scores (FRS) from baseline were greatest after CanolaDHA (-19.0 ± 3.1%; P < 0.001) than after other treatments (P < 0.05). CONCLUSION Consumption of CanolaDHA, a novel DHA-rich canola oil, improves HDL cholesterol, triglycerides, and blood pressure, thereby reducing FRS compared with other oils varying in unsaturated fatty acid composition. This trial was registered at www.clinicaltrials.gov as NCT01351012.

[1]  P. Kris-Etherton,et al.  Plasma fatty acid changes following consumption of dietary oils containing n-3, n-6, and n-9 fatty acids at different proportions: preliminary findings of the Canola Oil Multicenter Intervention Trial (COMIT) , 2014, Trials.

[2]  J. Danesh,et al.  Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. , 2014, Annals of internal medicine.

[3]  M. Bauer,et al.  Omega-3 fatty acids lower blood pressure by directly activating large-conductance Ca2+-dependent K+ channels , 2013, Proceedings of the National Academy of Sciences.

[4]  I. Buchan,et al.  Contributions of treatment and lifestyle to declining CVD mortality: why have CVD mortality rates declined so much since the 1960s? , 2012, Heart.

[5]  John Spertus,et al.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.

[6]  W. Harris,et al.  Effects of Marine-Derived Omega-3 Fatty Acids on Systemic Hemodynamics at Rest and During Stress: a Dose–Response Study , 2012, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[7]  J. Buzby,et al.  Dietary Assessment of Major Trends in U.S. Food Consumption, 1970-2005 , 2012 .

[8]  E. Riboli,et al.  Plasma Phospholipid Fatty Acid Concentration and Incident Coronary Heart Disease in Men and Women: The EPIC-Norfolk Prospective Study , 2012, PLoS medicine.

[9]  B. Chaitman,et al.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.

[10]  T. A. Jacobson,et al.  Effects of Eicosapentaenoic Acid Versus Docosahexaenoic Acid on Serum Lipids: A Systematic Review and Meta-Analysis , 2011, Current atherosclerosis reports.

[11]  Y. Yamori,et al.  Effects of Docosahexaenoic Acid Supplementation on Blood Pressure, Heart Rate, and Serum Lipids in Scottish Men with Hypertension and Hypercholesterolemia , 2011, International journal of hypertension.

[12]  John M. Davis,et al.  n-6 Fatty acid-specific and mixed polyunsaturate dietary interventions have different effects on CHD risk: a meta-analysis of randomised controlled trials , 2010, British Journal of Nutrition.

[13]  D. Jassal,et al.  High-oleic rapeseed (canola) and flaxseed oils modulate serum lipids and inflammatory biomarkers in hypercholesterolaemic subjects , 2010, British Journal of Nutrition.

[14]  B. de Roos,et al.  Long‐chain n‐3 polyunsaturated fatty acids: new insights into mechanisms relating to inflammation and coronary heart disease , 2009, British journal of pharmacology.

[15]  G. Eslick,et al.  Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. , 2009, International journal of cardiology.

[16]  D. Schoeller,et al.  Metabolic fate of saturated and monounsaturated dietary fats: the Mediterranean diet revisited from epidemiological evidence to cellular mechanisms. , 2009, Progress in lipid research.

[17]  D. Mozaffarian,et al.  Omega-6 Fatty Acids and Risk for Cardiovascular Disease: A Science Advisory From the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention , 2009, Circulation.

[18]  J. Sundström,et al.  Markers of dietary fat quality and fatty acid desaturation as predictors of total and cardiovascular mortality: a population-based prospective study. , 2008, The American journal of clinical nutrition.

[19]  J. Buckley,et al.  Dose-dependent effects of docosahexaenoic acid-rich fish oil on erythrocyte docosahexaenoic acid and blood lipid levels , 2008, British Journal of Nutrition.

[20]  A. Farmer,et al.  Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. , 2008, The Cochrane database of systematic reviews.

[21]  P. Kris-Etherton,et al.  Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states. , 2007, The American journal of clinical nutrition.

[22]  E. Ros,et al.  Acute effects of high-fat meals enriched with walnuts or olive oil on postprandial endothelial function. , 2006, Journal of the American College of Cardiology.

[23]  T. Mori,et al.  OMEGA‐3 FATTY ACIDS AND HYPERTENSION IN HUMANS , 2006, Clinical and experimental pharmacology & physiology.

[24]  J. Hibbeln,et al.  Healthy intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity. , 2006, The American journal of clinical nutrition.

[25]  B. Rosner,et al.  Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. , 2005, JAMA.

[26]  L. Niskanen,et al.  Prediction of cardiovascular mortality in middle-aged men by dietary and serum linoleic and polyunsaturated fatty acids. , 2005, Archives of internal medicine.

[27]  T. Sanders,et al.  LDL cholesterol-raising effect of low-dose docosahexaenoic acid in middle-aged men and women. , 2004, The American journal of clinical nutrition.

[28]  Lawrence J Appel,et al.  Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[29]  R. Holman,et al.  The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). , 2001, Clinical science.

[30]  L. Hodson,et al.  The effect of replacing dietary saturated fat with polyunsaturated or monounsaturated fat on plasma lipids in free-living young adults , 2001, European Journal of Clinical Nutrition.

[31]  P. Kris-Etherton,et al.  High-monounsaturated fatty acid diets lower both plasma cholesterol and triacylglycerol concentrations. , 1999, The American journal of clinical nutrition.

[32]  P. Calder,et al.  Cholesterol reduction using manufactured foods high in monounsaturated fatty acids: a randomized crossover study , 1999, British Journal of Nutrition.

[33]  W. A. Bradley,et al.  Triglyceride, high density lipoprotein, and coronary heart disease. , 1993, Consensus statement. National Institutes of Health Consensus Development Conference.

[34]  M. Mifflin,et al.  A new predictive equation for resting energy expenditure in healthy individuals. , 1990, The American journal of clinical nutrition.

[35]  S. Grundy,et al.  Influence of polyunsaturated fats on composition of plasma lipoproteins and apolipoproteins. , 1982, Journal of lipid research.

[36]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[37]  D. M. Morgan,et al.  Effects of ethyl arachidonate, cod-liver oil, and corn oil on the plasma-cholesterol level. A comparison in normal volunters. , 1961, Lancet.

[38]  D. Blankenhorn,et al.  Effect on Human Serum Lipids of Substituting Plant for Animal Fat in Diet.∗ , 1954, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[39]  S. Margen,et al.  Dietary modification of serum cholesterol and phospholipid levels. , 1952, The Journal of clinical endocrinology and metabolism.

[40]  G. Sanderson,et al.  Penicillin in subacute bacterial endocarditis. , 1946, Lancet.

[41]  P. Kris-Etherton,et al.  Cardiovascular disease risk of dietary stearic acid compared with trans, other saturated, and unsaturated fatty acids: a systematic review. , 2010, The American journal of clinical nutrition.